Allergy

The COVID-19 pandemic has placed burdens on access to in-person health services; therefore, safe and practical allergy management / prevention processes are necessary.

An expert offers 5 tips to physicians and patients on best practices for managing symptoms related to allergic asthma.

This edition from the 10 Year Plan features perspective from leadership at AAAAI and ACAAI, as well as survey results from allergists and pulmonologists.

An expert discusses how allergies can make it easier for viruses to enter the body as well as the association between asthma and COVID-19 severity.

Ketotifen fumarate ophthalmic solution 0.035% is the first and only over-the-counter preservative-free eye drop solution for itchy eyes caused by allergies.

An expert discusses the importance of getting vaccinated for the flu this year as well as strategies healthcare systems are taking to ensure easy access for patients.

D. farinae and D. pteronyssinus positive skin prick test results were much more frequent in patients >18 years.

Distinguishing factors between the 3.

How the treatment differs from others for peanut allergy.

The expert discusses the first FDA-approved drug of its kind for peanut allergy.

The findings suggest the need to possibly revise published food allergy guidelines.

Until more is known about long-term cardiac mechanisms behind MIS-C, providers could consider following Kawasaki disease guidelines for follow-up care

It has been notoriously difficult to measure sensitization to the alpha-Gal carbohydrate.

The findings provide data to help physicians, patients, and caregivers make informed, shared decisions on the management of peanut allergy.

Although a majority of pediatricians are aware of the guidelines, less than one-third of survey respondents report full implementation.

The results further support the overall benefit of epicutaneous immunotherapy.

There is also an association between late onset of spring and an increase in hospital admissions for asthma.

The biologic has now shown significant efficacy in treating 4 different atopic or type 2 inflammatory diseases.

The newest indication for the add-on biologic grants it use in children aged 6-11 years old with moderate to severe, uncontrolled atopic dermatitis.

A look at how the antibody influences the pathology of encephalitis, and how it can be properly assessed and treated.

The IL-17A-targeting biologic has now been indicated for pediatric plaque psoriasis—marking its fourth indication for patients with chronic diseases.

A new summary of recent cow's milk allergy guidelines show conlficting consensus on identifying and caring for infantile allergic symptoms.

Clinical investigator and allergist Jonathan Corren, MD, shares insight on the TSLP inhibitor.

New data shows higher rates of cancer and cardiovascular disease deaths for patients with celiac disease.

New pivotal phase 3 findings support an upcoming sBLA for the IL4 and IL13-targeting agent.